{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:44:54Z","timestamp":1787071494473,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,7]]},"abstract":"\n Context:<\/jats:title>\n Tumoral calcinosis is a disorder of phosphate metabolism characterized by ectopic calcification around major joints. Surgery is the current treatment of choice, but a suboptimal choice in recurrent and multicentric lesions.<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n To evaluate the efficacy of bisphosphonates for the management of tumoral calcinosis on optimized medical treatment.<\/jats:p>\n <\/jats:sec>\n \n Settings and Design:<\/jats:title>\n The study was done in the endocrine department of a tertiary care hospital in South India. We prospectively studied two patients with recurrent tumoral calcinosis who had failed therapy with phosphate lowering measures.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n After informed consent, we treated both patients with standard age adjusted doses of bisphosphonates for 18 months. The response was assessed by X ray and whole body 99mTc-methylene diphosphonate bone scan at the beginning of therapy and at the end of 1 year. We also estimated serum phosphate levels and urinary phosphate to document serial changes.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Two patients (aged 19 and 5 years) with recurrent idiopathic hyperphosphatemic tumoral calcinosis, following surgery were studied. Both patients had failed therapy with conventional medical management \u2212 low phosphate diet and phosphate binders. They had restriction of joint mobility. Both were given standard doses of oral alendronate and parenteral pamidronate respectively for more than a year, along with phosphate lowering measures. At the end of 1 year, one of the patients had more than 95% and 90% reduction in the size of the lesions in right and left shoulder joints respectively with total improvement in range of motion. In contrast, the other patient (5-year-old) had shown no improvement, despite continuing to maintain normophosphatemia following treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n Bisphosphonate therapy in tumoral calcinosis is associated with lesion resolution and may be used as a viable alternative to surgery, especially in cases with multicentric recurrence or treatment failure to other drugs.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/2230-8210.137511","type":"journal-article","created":{"date-parts":[[2014,7,23]],"date-time":"2014-07-23T07:26:23Z","timestamp":1406100383000},"page":"521-525","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Differential response of idiopathic sporadic tumoral calcinosis to bisphosphonates"],"prefix":"10.4103","volume":"18","author":[{"given":"Karthik","family":"Balachandran","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadishkumar","family":"Kamalanathan","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaya Prakash","family":"Sahoo","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Das","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhanapathi","family":"Halanaik","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, Jawaharlal Institute of Post Graduate Medical Education and Research, Puducherry, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260327","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2169\/internalmedicine.47.0730","article-title":"Physiological regulation and disorders of phosphate metabolism--pivotal role of fibroblast growth factor 23","volume":"47","author":"Fukumoto","year":"2008","journal-title":"Intern Med"},{"key":"R2-20260327","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1066896912444925","article-title":"Tumoral calcinosis--a pathogenetic overview: A histological and ultrastructural study with a report of two new cases, one in infancy","volume":"20","author":"Slavin","year":"2012","journal-title":"Int J Surg Pathol"},{"key":"R3-20260327","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.berh.2011.10.020","article-title":"Miscellaneous non-inflammatory musculoskeletal conditions. Hyperphosphatemic familial tumoral calcinosis (FGF23, GALNT3 and \u03b1Klotho)","volume":"25","author":"Farrow","year":"2011","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R4-20260327","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1177\/230949900901700328","article-title":"Medical treatment for tumoral calcinosis with eight years of follow-up: A report of four cases","volume":"17","author":"Alkhooly","year":"2009","journal-title":"J Orthop Surg (Hong Kong)"},{"key":"R5-20260327","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1210\/jc.2006-0305","article-title":"The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis","volume":"91","author":"Garringer","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"4 Suppl","key":"R6-20260327","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/8756-3282(95)00019-A","article-title":"Successful treatment of hyperphosphatemic tumoral calcinosis with long-term acetazolamide","volume":"16","author":"Yamaguchi","year":"1995","journal-title":"Bone"},{"key":"R7-20260327","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/BF03349921","article-title":"Effects of the acute subcutaneous administration of synthetic salmon calcitonin in tumoral calcinosis","volume":"12","author":"Candrina","year":"1989","journal-title":"J Endocrinol Invest"},{"key":"R8-20260327","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1067\/msy.1999.99193","article-title":"Tumoral calcinosis regression after subtotal parathyroidectomy: A case presentation and review of the literature","volume":"126","author":"Thakur","year":"1999","journal-title":"Surgery"},{"key":"R9-20260327","doi-asserted-by":"crossref","first-page":"3826","DOI":"10.1002\/art.34628","article-title":"Dramatic diminution of a large calcification treated with topical sodium thiosulfate","volume":"64","author":"Ratsimbazafy","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R10-20260327","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4158\/EP.13.2.182","article-title":"Idiopathic sporadic tumoral calcinosis of the hip: Successful oral bisphosphonate therapy","volume":"13","author":"Jacob","year":"2007","journal-title":"Endocrine Pract"},{"key":"R11-20260327","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","article-title":"Bisphosphonates: The first 40 years","volume":"49","author":"Russell","year":"2011","journal-title":"Bone"},{"key":"R12-20260327","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1259\/0007-1285-47-562-734","article-title":"Tumoral calcinosis with sedimentation sign","volume":"47","author":"Hug","year":"1974","journal-title":"Br J Radiol"},{"key":"R13-20260327","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1055\/s-2007-996264","article-title":"Tumoral calcinosis. Observations during six years","volume":"12","author":"Leicht","year":"1980","journal-title":"Horm Metab Res"},{"key":"R14-20260327","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0002-9343(99)00283-1","article-title":"Vitamin D, parathyroid hormone, and calcium: A complex regulatory network","volume":"107","author":"Feldman","year":"1999","journal-title":"Am J Med"},{"key":"R15-20260327","doi-asserted-by":"crossref","first-page":"4472","DOI":"10.1210\/jc.2006-1247","article-title":"Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene","volume":"91","author":"Ichikawa","year":"2006","journal-title":"J Clin Endocrinol Metabol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/02223308-201418040-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:46:58Z","timestamp":1787068018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/02223308-201418040-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.4103\/2230-8210.137511","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7]]}}}